Similar articles for PMID: 22678727

Year	Number of Results
1989	1
1990	1
1992	1
1995	2
1997	1
1998	2
1999	1
2001	1
2002	1
2003	1
2004	2
2005	4
2006	5
2007	5
2008	6
2009	12
2010	1
2011	8
2012	9
2013	12
2014	7
2015	6
2016	6
2017	2
2018	2
2019	8
2020	2
2021	1
2022	3
2023	3
2024	0

1

Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.

Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, Apostoli A, Marcantoni C, Calabresi A, Dal Zoppo S, Bigoni S, Regazzi M. Matteelli A, et al. J Antimicrob Chemother. 2012 Oct;67(10):2470-3. doi: 10.1093/jac/dks218. Epub 2012 Jun 7. J Antimicrob Chemother. 2012. PMID: 22678727

2

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R. Zhang J, et al. J Antimicrob Chemother. 2011 Sep;66(9):2075-82. doi: 10.1093/jac/dkr266. Epub 2011 Jun 28. J Antimicrob Chemother. 2011. PMID: 21712242 Clinical Trial.

3

Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA. Boulanger C, et al. Clin Infect Dis. 2009 Nov 1;49(9):1305-11. doi: 10.1086/606056. Clin Infect Dis. 2009. PMID: 19807276 Clinical Trial.

4

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.

Chokephaibulkit K, Nuntarukchaikul M, Phongsamart W, Wittawatmongkol O, Lapphra K, Vanprapar N, Cressey TR. Chokephaibulkit K, et al. J Antimicrob Chemother. 2012 Dec;67(12):2927-31. doi: 10.1093/jac/dks332. Epub 2012 Aug 23. J Antimicrob Chemother. 2012. PMID: 22923483 Clinical Trial.

5

Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

Khachi H, O'Connell R, Ladenheim D, Orkin C. Khachi H, et al. J Antimicrob Chemother. 2009 Oct;64(4):871-3. doi: 10.1093/jac/dkp263. Epub 2009 Jul 22. J Antimicrob Chemother. 2009. PMID: 19628472 No abstract available.

6

Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.

Saleri N, Dembélé SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, Nacanabo R, Kouanda S, Comelli M, Regazzi M, Matteelli A. Saleri N, et al. J Antimicrob Chemother. 2012 Feb;67(2):469-72. doi: 10.1093/jac/dkr445. Epub 2011 Oct 25. J Antimicrob Chemother. 2012. PMID: 22028201

7

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.

Ouedraogo HG, Matteelli A, Sulis G, Compaore TR, Diagbouga S, Tiendrebeogo S, Roggi A, Cisse K, Giorgetti PF, Villani P, Sangare L, Simpore J, Regazzi M, Kouanda S. Ouedraogo HG, et al. Ann Clin Microbiol Antimicrob. 2020 Jan 22;19(1):3. doi: 10.1186/s12941-020-0345-6. Ann Clin Microbiol Antimicrob. 2020. PMID: 31969147 Free PMC article.

8

A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.

Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. Gallicano K, et al. Clin Pharmacol Ther. 2001 Aug;70(2):149-58. doi: 10.1067/mcp.2001.117612. Clin Pharmacol Ther. 2001. PMID: 11503009 Clinical Trial.

9

Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.

Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A. Seminari E, et al. J Antimicrob Chemother. 2007 Oct;60(4):831-6. doi: 10.1093/jac/dkm282. Epub 2007 Aug 7. J Antimicrob Chemother. 2007. PMID: 17684056

10

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.

Kouanda S, Ouedraogo HG, Cisse K, Compaoré TR, Sulis G, Diagbouga S, Roggi A, Tarnagda G, Villani P, Sangare L, Simporé J, Regazzi M, Matteelli A. Kouanda S, et al. BMC Infect Dis. 2020 Jun 26;20(1):449. doi: 10.1186/s12879-020-05169-2. BMC Infect Dis. 2020. PMID: 32590942 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

105 results

Results by year